Growth Metrics

Integra Lifesciences Holdings (IART) Depreciation & Amortization (CF) (2016 - 2026)

Integra Lifesciences Holdings' Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $38.4 million for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 2.24% to $38.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $151.8 million, a 7.76% increase, with the full-year FY2025 number at $151.8 million, up 7.76% from a year prior.
  • Depreciation & Amortization (CF) hit $38.4 million in Q4 2025 for Integra Lifesciences Holdings, roughly flat from $38.5 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for IART hit a ceiling of $38.5 million in Q3 2025 and a floor of $29.2 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $32.7 million across 5 years, with a median of $30.8 million in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): fell 4.07% in 2022 and later increased 21.66% in 2025.
  • Tracing IART's Depreciation & Amortization (CF) over 5 years: stood at $30.7 million in 2021, then decreased by 4.07% to $29.5 million in 2022, then grew by 5.05% to $31.0 million in 2023, then increased by 21.31% to $37.6 million in 2024, then rose by 2.24% to $38.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for IART at $38.4 million in Q4 2025, $38.5 million in Q3 2025, and $37.7 million in Q2 2025.